Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Claritas Pharmaceuticals Inc (KALTF)

Claritas Pharmaceuticals Inc (KALTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KALTF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1100 unch
on 03/15/22
0.1900 -42.11%
on 03/02/22
-0.0193 (-14.93%)
since 02/15/22
3-Month
0.1100 unch
on 03/15/22
0.2000 -45.00%
on 12/16/21
-0.0102 (-8.49%)
since 12/15/21
52-Week
0.0300 +266.67%
on 07/30/21
1.3600 -91.91%
on 04/19/21
-0.7700 (-87.50%)
since 03/15/21

Most Recent Stories

More News
Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

Ethics Committee Approval is Final Step Prior to Enrollment of Claritas’ Phase 1 Clinical Study of R-107...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or...

CLAS.VN : 0.025 (-16.67%)
OTC.VN : 0.325 (-4.41%)
KLY.VN : 0.045 (unch)
KALTF : 0.1100 (unch)
Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Claritas to Initiate Phase 2 Clinical Testing of R-107 in Treatment of COVID-Related Sepsis Following Completion of Phase 1 Study...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Provides Update Regarding Phase 1 Clinical Study

SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (-4.41%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.1248
2nd Resistance Point 0.1219
1st Resistance Point 0.1159
Last Price 0.1100
1st Support Level 0.1070
2nd Support Level 0.1041
3rd Support Level 0.0981

See More

52-Week High 1.3600
Fibonacci 61.8% 0.8519
Fibonacci 50% 0.6950
Fibonacci 38.2% 0.5381
Last Price 0.1100
52-Week Low 0.0300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar